Evernow, MD-Led Platform

Evernow is a San Francisco-based menopause telehealth company founded in 2021 by Alicia Jackson, a former NASA research scientist who pivoted to women's health after her own frustrating experience navigating perimenopause care. The company is built on the premise that menopause is systematically undertreated — fewer than 7% of OB/GYNs receive dedicated training in menopause medicine — and that a subscription-based, clinician-led platform can deliver evidence-based hormone therapy at the pace and convenience patients actually need. Evernow's clinical model centers on asynchronous communication as the primary care channel. Unlike platforms that rely on scheduled video visits as the main touchpoint, Evernow gives members 24/7 access to their care team through an in-app messaging interface. This means a patient noticing breakthrough bleeding on her current estrogen dose can reach her clinician without waiting for the next available appointment slot. The model reflects a recognition that menopause management is ongoing and iterative — finding the right hormone formulation and dose often requires multiple small adjustments over months. The platform prescribes both conventional and bioidentical hormone options, including estradiol patches, creams, gels, vaginal preparations, and oral micronized progesterone. Clinicians also offer non-hormonal treatments for patients who cannot or prefer not to use HRT, including low-dose SSRIs and SSNRIs for vasomotor symptoms and sleep-focused interventions. Evernow accepts insurance for video consultations and for most FDA-approved prescription medications, making the out-of-pocket medication cost manageable for many patients even on the standard membership. The company raised $28.5 million in Series A funding in 2022, which it used to expand its clinician network and state coverage. As of 2025, Evernow is available in more than 35 states including California, New York, Texas, Florida, Illinois, and most of the Southeast and Midwest. The company has been particularly active in publishing educational content on menopause science, positioning itself as both a clinical service and an information resource for the estimated 6,000 women who enter menopause each day in the United States. For patients who prioritize responsiveness and convenience over the depth of a full-spectrum primary care relationship, Evernow's messaging-forward model offers a meaningfully different experience from traditional telehealth platforms that are built around the 15-minute scheduled video visit. The company is built on the premise that menopause is systematically undertreated — fewer than 7% of OB/GYNs receive dedicated training in menopause medicine — and that a subscription-based, clinician-led platform can deliver evidence-based hormone therapy at the pace and convenience patients actually need. Evernow's clinical model centers on asynchronous communication as the primary care channel. Unlike platforms that rely on scheduled video visits as the main touchpoint, Evernow gives members 24/7 access to their care team through an in-app messaging interface. This means a patient noticing breakthrough bleeding on her current estrogen dose can reach her clinician without waiting for the next available appointment slot. The model reflects a recognition that menopause management is ongoing and iterative — finding the right hormone formulation and dose often requires multiple small adjustments over months. The platform prescribes both conventional and bioidentical hormone options, including estradiol patches, creams, gels, vaginal preparations, and oral micronized progesterone. Clinicians also offer non-hormonal treatments for patients who cannot or prefer not to use HRT, including low-dose SSRIs and SSNRIs for vasomotor symptoms and sleep-focused interventions. Evernow accepts insurance for video consultations and for most FDA-approved prescription medications, making the out-of-pocket medication cost manageable for many patients even on the standard membership. The company raised $28.5 million in Series A funding in 2022, which it used to expand its clinician network and state coverage. As of 2025, Evernow is available in more than 35 states including California, New York, Texas, Florida, Illinois, and most of the Southeast and Midwest. The company has been particularly active in publishing educational content on menopause science, positioning itself as both a clinical service and an information resource for the estimated 6,000 women who enter menopause each day in the United States. For patients who prioritize responsiveness and convenience over the depth of a full-spectrum primary care relationship, Evernow's messaging-forward model offers a meaningfully different experience from traditional telehealth platforms that are built around the 15-minute scheduled video visit.